Company news

Keros Therapeutics, Inc. news in 2020

Keros Therapeutics, Inc.'s news releases, calls and decks from 2020, newest first.

View company

Keros Therapeutics Announces Addition to NASDAQ Biotechnology Index

December 20, 2020

Keros Therapeutics Appoints Mary Ann Gray, Ph.D., to its Board of Directors

December 16, 2020

Keros Therapeutics Presents Clinical Trial and Preclinical Study Results from its ALK2 Inhibitor Program, Including KER-047 Phase 1 Data, and KER-050 Preclinical Data, at the Virtual 62nd American Society of Hematology Annual Meeting and Exposition

December 6, 2020

Keros Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares

November 16, 2020

Keros Therapeutics Announces Pricing of Public Offering of Common Stock

November 11, 2020

Keros Therapeutics Reports Recent Business Highlights and Third Quarter 2020 Financial Results

November 9, 2020

Keros Therapeutics to Present at the Virtual 62nd American Society of Hematology Annual Meeting and Exposition

November 3, 2020

Keros Therapeutics, Inc. Announces Dosing of First Participants in Phase 2 Clinical Trial of KER-050 in Myelodysplastic Syndromes (MDS)

October 19, 2020

Keros Therapeutics to Present at the H.C. Wainwright 22nd Annual Global Investment Conference

September 13, 2020

Keros Therapeutics Presents Results from Preclinical Studies Investigating KER-012 at the American Society for Bone and Mineral Research 2020 Annual Meeting

September 10, 2020

Keros Therapeutics Reports Recent Business Highlights and Second Quarter 2020 Financial Results

August 12, 2020

Keros Therapeutics to be Featured on The Balancing Act's "Behind the Mystery" Rare Disease Series

August 9, 2020

Keros Therapeutics, Inc. Announces Completion of Dosing of Planned Cohorts in KER-047 Phase 1 Trial and Provides Program Update

August 3, 2020

Keros Therapeutics Set to Join Russell 2000® Index

June 25, 2020

Keros Therapeutics Presents Results from Clinical and Preclinical Studies Investigating KER-050, along with Preclinical Data from its ALK2 Inhibitor Program, at the European Hematology Association 2020 Annual Meeting

June 11, 2020

Keros Therapeutics To Present At The Jefferies 2020 Virtual Healthcare Conference

May 27, 2020

Keros Therapeutics Reports Recent Business Highlights and First Quarter 2020 Financial Results

May 21, 2020

Keros Therapeutics to Present at the Virtual 25th Annual Congress of the European Hematology Association

May 13, 2020

Keros Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

April 12, 2020

Keros Therapeutics Announces Pricing of Initial Public Offering of Common Stock

April 6, 2020

Decks in 2020